EMEA-002648-PIP01-19
Key facts
| Active substance |
Recombinant anti-human CD20 and anti-human CD3 monoclonal antibody (RO7082859; CD20 CD3 TCB)
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0094/2020
|
| PIP number |
EMEA-002648-PIP01-19
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of mature B-cell neoplasms
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Roche Registration GmbH
Tel. +41 616879411 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|